Treatment of systemic mast cell disease: Beyond interferon

Leukemia Research

Volumn 28, Issue 3, 2004, Pages 223-224

  Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLADRIBINE; CORTICOSTEROID; IMATINIB; PREDNISONE; RECOMBINANT ALPHA INTERFERON;

BLOOD DISEASE; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL FEATURE; DISEASE CLASSIFICATION; EDITORIAL; HUMAN; MAST CELL LEUKEMIA; PRIORITY JOURNAL; PROGNOSIS; SARCOMA; SYSTEMIC MAST CELL DISEASE;

EID: 0345734183     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2003.09.004     Document Type: Editorial

References (22)

1. Fearfield L.A., Francis N., Henry K., Costello C., Bunker C.B. Bone marrow involvement in cutaneous mastocytosis. Br. J. Dermatol. 144(3):2001;561-566.
2. Tebbe B., Stavropoulos P.G., Krasagakis K., Orfanos C.E. Cutaneous mastocytosis in adults evaluation of 14 patients with respect to systemic disease manifestations. Dermatology. 197(2):1998;101-108.
3. Travis W.D., Li C.Y., Bergstralh E.J., Yam L.T., Swee R.G. Systemic mast cell disease. Analysis of 58 cases and literature review. Medicine. 67(6):1988;345-368.
4. Lawrence J.B., Friedman B.S., Travis W.D., Chinchilli V.M., Metcalfe D.D., Gralnick H.R. Hematologic manifestations of systemic mast cell disease: a prospective study of laboratory and morphologic features and their relation to prognosis. Am. J. Med. 91(6):1991;612-624.
5. Valent P., Horny H.P., Escribano L.et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk. Res. 25(7):2001;603-625.
6. Czarnetzki B.M., Algermissen B., Jeep S.et al. Interferon treatment of patients with chronic urticaria and mastocytosis. J. Am. Acad. Dermatol. 30(3):1994;500-501.
7. Butterfield J.H. Response of severe systemic mastocytosis to interferon alpha. Br. J. Dermatol. 138(3):1998;489-495.
8. Worobec A.S., Kirshenbaum A.S., Schwartz L.B., Metcalfe D.D. Treatment of three patients with systemic mastocytosis with interferon alpha-2b. Leuk. Lymphoma. 22(5/6):1996;501-508.
9. Weide R., Ehlenz K., Lorenz W., Walthers E., Klausmann M., Pfluger K.H. Successful treatment of osteoporosis in systemic mastocytosis with interferon alpha-2b. Ann. Hematol. 72(1):1996;41-43.
10. Lehmann T., Beyeler C., Lammle B.et al. Severe osteoporosis due to systemic mast cell disease: successful treatment with interferon alpha-2B. Br. J. Rheumatol. 35(9):1996;898-900.
11. Hubner C., Wedding U., Strater J., Limberg B., Stremmel W. Clinical stable systemic mastocytosis with interferon alpha-2b therapy. J. Intern. Med. 241(6):1997;529-533.
12. Hauswirth AW, Simonitsch-Klupp I, Uffmann M, Koller E, Sperr WR, Valent P. Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature. Leuk Res 2004;28(3):249-57.
13. Pardini S., Bosincu L., Bonfigli S., Dore F., Longinotti M. Anaphylactic-like syndrome in systemic mastocytosis treated with alpha-2-interferon. Acta Haematol. 85(4):1991;220.
14. Casassus P., Caillat-Vigneron N., Martin A.et al. Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients. Br. J. Haematol. 119(4):2002;1090-1097.
15. Pardanani A., Elliott M., Reeder T.et al. Imatinib for systemic mast-cell disease. Lancet. 362:2003;535-536.
16. Pardanani A, Ketterling RP, Brockman SR, et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib therapy. Blood, First Edition Paper, prepublished online July 3, 2003; DOI 10.1182/blood-2003-05-1627: DOI 10.
17. Tefferi A., Li C.Y., Butterfield J.H., Hoagland H.C. Treatment of systemic mast-cell disease with cladribine. N. Engl. J. Med. 344(4):2001;307-309.
18. Pardanani A, Hoffbrand AV, Butterfield JH, Tefferi A. Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine. Leuk Res (in press).
19. Zermati Y., De Sepulveda P., Feger F. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. Oncogene. 22(5):2003;660-664.
20. Cools J., DeAngelo D.J., Gotlib J.et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med. 348(13):2003;1201-1214.
21. Kirshenbaum A.S., Goff J.P., Semere T., Foster B., Scott L.M., Metcalfe D.D. Demonstration that human mast cells arise from a progenitor cell population that is CD34(+), c-kit(+), and expresses aminopeptidase N (CD13). Blood. 94(7):1999;2333-2342.
22. Carrera C.J., Terai C., Lotz M.et al. Potent toxicity of 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo. A novel approach to immunosuppressive therapy. J. Clin. Invest. 86(5):1990;1480-1488.